Jeremy Levin, Ovid CEO
Two years after a ‘positive’ result tanked their stock, Ovid's Jeremy Levin wins a partner for the PhIII journey
If Jeremy Levin could do it over again, he says he would.
Two years ago, his company, Ovid Therapeutics, released the topline data from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
